CSIMarket
 


Quidel Corporation  (QDEL)
Other Ticker:  
 
 

QDEL's EPS from Cont. Operations Growth by Quarter and Year

Quidel's EPS from Cont. Operations results by quarter and year




QDEL EPS from Cont. Operations (in $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 5.48 0.38 0.90
III Quarter September - 5.52 0.39 0.28
II Quarter June 0.46 1.61 0.03 -0.08
I Quarter March 4.19 0.96 0.63 0.96
FY   4.65 13.57 1.43 2.06



QDEL EPS from Cont. Operations second quarter 2021 Y/Y Growth Comment
Quidel Corporation reported drop in EPS from Cont. Operations in the second quarter by -71.43% to $ 0.46 , from the same quarter in 2020.
The fall in the second quarter Quidel Corporation's EPS from Cont. Operations compares unfavorably to the Company's average EPS from Cont. Operations rise of 28.45%.

Looking into second quarter results within In Vitro & In Vivo Diagnostic Substances industry 15 other companies have achieved higher EPS from Cont. Operations growth. While Quidel Corporation' s EPS from Cont. Operations meltdown of -71.43% ranks overall at the positon no. 1560 in the second quarter.




QDEL EPS from Cont. Operations ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 1342.11 % -57.78 % -
III Quarter September - 1315.38 % 39.29 % -
II Quarter June -71.43 % 5266.67 % - -
I Quarter March 336.46 % 52.38 % -34.38 % 123.26 %
FY   - 848.95 % -30.58 % -

Financial Statements
Quidel's second quarter 2021 EPS from Cont. Operations $ 0.46 QDEL's Income Statement
Quidel's second quarter 2020 EPS from Cont. Operations $ 1.61 Quarterly QDEL's Income Statement
New: More QDEL's historic EPS from Cont. Operations Growth >>


QDEL EPS from Cont. Operations (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - -0.72 % -2.56 % 221.43 %
III Quarter September - 242.86 % 1200 % -
II Quarter June -89.02 % 67.71 % -95.24 % -
I Quarter March -23.54 % 152.63 % -30 % -
FY (Year on Year)   - 848.95 % -30.58 % -




EPS from Cont. Operations second quarter 2021 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #16
Healthcare Sector #102
Overall #1560

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
153.82 % 28.45 % -99.36 %
(Sep 30 2020)   (Jun 30 2017)
EPS from Cont. Operations second quarter 2021 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #16
Healthcare Sector #102
Overall #1560
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
153.82 % 28.45 % -99.36 %
(Sep 30 2020)   (Jun 30 2017)

EPS from Cont. Operations by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Quidel's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
1200 % 126.65 % -95.24 %
(Sep 30 2019)  


QDEL's II. Quarter Q/Q EPS from Cont. Operations Comment
In the II. Quarter 2021 Quidel Corporation reported fall in EPS from Cont. Operations from the first quarter by -89.02% to $ 0.46 , from $ 4.19 declared a quarter before.

Those periodic circumstance which normally fuel II. Quarter 2021 results, could not salvage the II. Quarter for the Quidel Corporation, Ana Marques, a business insider from Paris said, she detected further challenges down the road for the In Vitro & In Vivo Diagnostic Substances's company and continued that average sequential EPS from Cont. Operations growth is at 126.65% for the In Vitro & In Vivo Diagnostic Substances's company.

Within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While Quidel's EPS from Cont. Operations growth quarter on quarter, overall rank is 1824.


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #17
Healthcare Sector #135
Overall #1824
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #17
Healthcare Sector #135
Overall #1824
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
1200 % 126.65 % -95.24 %
(Sep 30 2019)  


QDEL's II. Quarter Q/Q EPS from Cont. Operations Comment
In the II. Quarter 2021 Quidel Corporation disclosed fall in EPS from Cont. Operations from the first quarter by -89.02% to $ 0.46 , from $ 4.19 achived in the previous quarter.

Those periodic circumstance which commonly elevate II. Quarter 2021 results, have not salvage the II. Quarter for the Quidel Corporation, Ana Marques, a business insider from Paris pointed out and mentioned that average quarter on quarter EPS from Cont. Operations growth is at 126.65% for the In Vitro & In Vivo Diagnostic Substances's company.

Within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While Quidel's EPS from Cont. Operations growth quarter on quarter, overall rank is 1824.


Quidel's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
Cumulative EPS from Cont. Operations 12 Months Ending $ 15.65 $ 16.80 $ 13.57 $ 8.47 $ 3.34
Y / Y EPS from Cont. Operations Growth (TTM) 369.11 % 856.92 % 851.86 % 333.23 % 80.87 %
Year on Year EPS from Cont. Operations Growth Overall Ranking # 102 # 33 # 17 # 32 # 180
Seqeuential EPS from Cont. Operations Change (TTM) -6.85 % 23.81 % 60.25 % 153.82 % 90.02 %
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # 1560 # 481 # 219 # 15 # 88




Cumulative EPS from Cont. Operations growth Comment
With the quarterly EPS from Cont. Operations reported in the Jun 30 2021 period, Quidel's cumulative twelve months EPS from Cont. Operations were $ 16 , company would post below average annual EPS from Cont. Operations growth of 90.02% year on year, if the fiscal year would end at Jun 30 2021.
A slow-down in the Quidel's EPS from Cont. Operations growth from the 4.19% growth in Mar 31 2021.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 33 to 102.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
153.82 %
28.45 %
-99.36 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 16
Healthcare Sector # 10
Overall # 102

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
79566.41 %
6916.48 %
-30.95 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 102
S&P 500 # 1560
Cumulative EPS from Cont. Operations growth Comment
With the quarterly EPS from Cont. Operations reported in the Jun 30 2021 period, Quidel's cumulative twelve months EPS from Cont. Operations were $ 16 , company would post below average annual EPS from Cont. Operations growth of -30.95% year on year, if the fiscal year would end at Jun 30 2021.
A slow-down in the Quidel's EPS from Cont. Operations growth from the 4.19% growth in Mar 31 2021.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 33 to 102.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
153.82 %
28.45 %
-99.36 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 16
Healthcare Sector # 10
Overall # 102

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
79566.41 %
6916.48 %
-30.95 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 102
S&P 500 # 1560




Other EPS from Cont. Operations Growth
In Vitro & In Vivo Diagnostic Substances Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
QDEL's EPS from Cont. Operations Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for QDEL's Competitors
EPS from Cont. Operations Growth for Quidel's Suppliers
EPS from Cont. Operations Growth for QDEL's Customers

You may also want to know
QDEL's Annual Growth Rates QDEL's Profitability Ratios QDEL's Asset Turnover Ratio QDEL's Dividend Growth
QDEL's Roe QDEL's Valuation Ratios QDEL's Financial Strength Ratios QDEL's Dividend Payout Ratio
QDEL's Roa QDEL's Inventory Turnover Ratio QDEL's Growth Rates QDEL's Dividend Comparisons



Companies with similar EPS from Cont. Operations fall for the quarter ending Jun 30 2021 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Jun 30 2021
Eli Lilly And Company-1.92%$ -1.923 
Bio rad Laboratories Inc -5.77%$ -5.769 
Corcept Therapeutics Inc-8.00%$ -8.000 
Zynex Inc-11.11%$ -11.111 
Lhc Group Inc-15.97%$ -15.972 
U S Physical Therapy Inc-17.17%$ -17.172 
Reynolds Consumer Products Inc -28.30%$ -28.302 
Chemed Corporation-30.81%$ -30.814 
Msa Safety Inc-31.18%$ -31.183 
Supernus Pharmaceuticals inc -31.82%$ -31.818 
Co diagnostics Inc -37.04%$ -37.037 
Petmed Express Inc-43.59%$ -43.590 
The Pennant Group Inc -43.75%$ -43.750 
Hill rom Holdings Inc -47.52%$ -47.518 
Neurocrine Biosciences Inc -47.67%$ -47.674 
Incyte Corp-48.87%$ -48.872 
Meridian Bioscience Inc -57.81%$ -57.813 
Healthcare Services Group Inc -58.06%$ -58.065 
Molecular Templates Inc -58.82%$ -58.824 
Merck and Co Inc -59.66%$ -59.664 
Sunlink Health Systems Inc-60.74%$ -60.735 
Pro Dex Inc-65.05%$ -65.053 
Vyne Therapeutics Inc -67.77%$ -67.769 
Hanger inc -68.29%$ -68.293 
Biogen Inc -68.75%$ -68.750 
Tivity Health Inc -69.49%$ -69.492 
Electromed Inc -69.92%$ -69.920 
Quidel Corporation-71.43%$ -71.429 
Alpha Pro Tech Ltd-72.34%$ -72.340 
Amgen Inc -73.62%$ -73.616 


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PUYI's Profile

Stock Price

PUYI's Financials

Business Description

Fundamentals

Charts & Quotes

PUYI's News

Suppliers

PUYI's Competitors

Customers & Markets

Economic Indicators

PUYI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071